PMID- 36330095
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221105
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The influence of pharmaceutical care in patients with advanced non-small-cell 
      lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 
      inhibitors.
PG  - 910722
LID - 10.3389/fphar.2022.910722 [doi]
LID - 910722
AB  - Background: Immune checkpoint inhibitors combined chemotherapy (ICIC) are widely 
      used for various types of lung cancer in the past decade. However, ICIC related 
      adverse events (AEs) are more serious than immune-related adverse events (irAE) 
      or cytotoxic chemotherapy alone. Objective: This prospective interventional study 
      aimed to evaluate the impact of the pharmaceutical care program in reducing 
      adverse events and analyze pharmacy interventions in patients with NSCLC who 
      receive ICIC therapies. Method: NSCLC patients were enrolled in this study, the 
      pharmaceutical care program was introduced after patients received the second 
      cycle ICIC therapies, and were followed by the pharmacist for 6 months after 
      hospital discharge. The percentages of adverse events between patients in and 
      after the first two cycles were analyzed and compared. Results: After the first 
      two treatment cycles, the clinical pharmacist proposed 67 interventions in 30 
      patients. The most frequent types of intervention were drug discontinuation 
      (40.3%, 27/67) followed by drug modification (14.9%, 10/67). There were 
      significant decreases in AEs after the second cycle with respect to nausea 
      (>/=grade-2, 14% vs. 28.3%, p = 0.039), constipation (>/=grade-2, 8.8% vs. 21.7%, p = 
      0.039), diarrhea (>/=grade-2, 6% vs. 16.7%, p = 0.031), and myelosuppression 
      (>/=grade-2, 15.8% vs. 30.0%, p = 0.022). Conclusion: Provision of pharmaceutical 
      care for NSCLC patients receiving ICIC therapies can optimize drug therapy and 
      reduce adverse events.
CI  - Copyright (c) 2022 Kou, Lin, Su, Xiang, Qiao, Wu and Hou.
FAU - Kou, Wen
AU  - Kou W
AD  - Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou, Gansu, 
      China.
FAU - Lin, Yan Yan
AU  - Lin YY
AD  - Department of General Surgery, First Hospital of Lanzhou University, Lanzhou, 
      Gansu, China.
FAU - Su, Fei
AU  - Su F
AD  - Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, 
      China.
FAU - Xiang, Yue
AU  - Xiang Y
AD  - United States Food and Drug Administration, Silver Spring, MD, United States.
FAU - Qiao, Hui
AU  - Qiao H
AD  - Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, 
      China.
FAU - Wu, Xin'An
AU  - Wu X
AD  - Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou, Gansu, 
      China.
FAU - Hou, Xiao-Ming
AU  - Hou XM
AD  - Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20221018
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9623061
OTO - NOTNLM
OT  - chemotherapy
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - non-small-cell lung cancer
OT  - pharmaceutical care
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/05 06:01
PMCR- 2022/10/18
CRDT- 2022/11/04 02:26
PHST- 2022/04/01 00:00 [received]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/11/04 02:26 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/05 06:01 [medline]
PHST- 2022/10/18 00:00 [pmc-release]
AID - 910722 [pii]
AID - 10.3389/fphar.2022.910722 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Oct 18;13:910722. doi: 10.3389/fphar.2022.910722. 
      eCollection 2022.